<DOC>
	<DOCNO>NCT00287118</DOCNO>
	<brief_summary>Phase IIIb , open-label , multi-centre study establish psoriasis control moderate severe plaque psoriasis Raptiva therapy administer SC 24 week .</brief_summary>
	<brief_title>A Multicentre , Open Label Phase IIIb/IV Study Subcutaneously Administered Raptiva Treatment Adult Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A ) In opinion investigator , candidate systemic therapy psoriasis could include : Patients moderate severe plaque psoriasis define PASI &gt; 10 BSA &gt; 10 Patients follow may also deem require systemic therapy judgement physician : Severe psychosocial disability ( judgement physician ) , Nail psoriasis , Scalp psoriasis , Palmar plantar psoriasis etc OR B ) Subjects complete CLEAR study IMP 24011 wish continue Raptiva ( efalizumab ) therapy . Body weight 120 kg 18 75 year old For woman childbearing potential men whose partner become pregnant , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study 3 month last dose Raptiva Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study Agreement participate study Signed inform consent Discontinuation systemic psoriasis treatment prior commencement study drug . No washout period require agent prior start study receive first dose study drug ( Raptiva ) Discontinuation biologic agent ( Raptiva ) 3 month prior receive first dose study drug ( Raptiva ) Discontinuation PUVA , UVB treatment 28 day prior commencement receive first dose study drug . Discontinuation investigational drug treatment 3 month prior study day 0 per washout requirement previous protocol No vaccination ( e.g. , tetanus , booster , influenza vaccine ) least 14 day prior first dose study drug Treatment regimens b blocker , ACE inhibitor , antimalarial drug , quinidine , interferon , lithium stable least 28 day prior first dose study drug ( SD 0 ) Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis Active rebound psoriasis follow discontinuation previous Raptiva treatment ( PASI &gt; 125 % baseline and/or new predominant morphology psoriasis ) reason adverse event lack efficacy Raptiva . If due another non drug reason ( vaccination , infection ) patient include study . History severe allergic anaphylactic reaction humanise monoclonal antibody History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) . Patients undergo mandatory test screening . Patients positive HIV exclude . Pregnancy lactation WBC count &lt; 4000/L &gt; 14,000/L Patient history clinically significant thrombocytopenia , bleed disorder platelet count &lt; 100,000 cells/L Seropositivity hepatitis B C virus Patients undergo test screening . Patients positive hepatitis B antigen hepatitis C antibody exclude . Hepatic enzyme &gt; 3 time upper limit normal History active tuberculosis ( TB ) currently undergo treatment TB within one year prior study day 0 . Chest Xray ( within 3 month prior SD0 ) require highrisk patient ( appendix J ) . Patients positive chest Xray exclude . Presence malignancy within past 5 year , include lymphoproliferative disorder . Patients history fully resolve basal cell squamous cell skin cancer may enrol . Diagnosis hepatic cirrhosis , regardless cause severity Serum creatinine &gt; 2 time upper limit normal Hospital admission cardiac disease , stroke , pulmonary disease within last year History substance abuse within last 5 year Any medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>